The National Medical Products Administration has approved the launch of injection type Velasinase .

Recently, the National Medical Products Administration approved the application of Injection Vialase from Beihai Kangcheng Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for long-term enzyme replacement therapy for Gaucher disease patients with type I and type III who are 12 years old and older. Gaucher disease is a rare autosomal recessive inherited metabolic disorder caused by a deficiency in the function of glucocerebrosidase in lysosomes, and it is included in the "First Batch of Rare Disease Catalog". Injection Vialase can reduce the accumulation of glucocerebrosidase in the body, thereby exerting a therapeutic effect. The market approval of this variety provides new treatment options for related patients.